Release Date: 20 October 2022
The development of multispecific antibodies such bispecific, trispecific and tetraspecific antibodies was driven by the commercial success of monoclonal antibodies. Among these, bispecific antibodies were the first ones t...
Release Date: 30 August 2022
Global Orphan Cancer Drug Market, Drug Sales, Price and Clinical Trials Insight 2028 Report Highlights:
Release Date: 14 June 2022
Global Combination Cancer Immunotherapy Market Opportunity and Clinical Trials Insight 2028 Report Highlights:
Release Date: 09 June 2022
"Global KRAS Inhibitors Market and Clinical Trials Forecast 2028" Report Highlights:
Release Date: 26 April 2022
Global Bispecific Antibody Market Insight 2028 Report Highlights:
Release Date: 08 April 2022
Global Bispecific Antibody Market Insight 2028 Report Highlights:
Release Date: 08 April 2022
Global Trispecific Antibody Market Opportunity And Clinical Trials Insight 2028 Report Analysis and Data Highlights:
Release Date: 04 February 2022
Global LAG 3 Inhibitor Clinical Trials and Market Opportunity Insight 2028 Report Highlights:
Release Date: 04 February 2022
Global Orphan Disease Drugs Clinical Trials Insight 2028 Report Highlights:
Release Date: 13 January 2022
"Global Cell Therapy Market Outlook, Patent and Clinical Trials Insight 2028" Report Highlights:
Release Date: 26 November 2021
TIGIT Inhibitor Clinical Trials Intelligence Report Insight:
Release Date: 23 November 2021
Global Orphan Drugs Clinical Trials Insight Report Highlights:
Release Date: 17 November 2021
From more than 30 years, scientists have been developing therapeutic monoclonal antibodies which bind to single target antigens on cancer cell. Since their entry into the market, monoclonal antibodies are considered as ma...
Release Date: 02 November 2021
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028 Report Analysis and Data Highlights:
Release Date: 07 October 2021
Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient hypericin to treat the T-cell lymphoma disease. The ingredient is being developed by Soligenix, a company focusing on research and deve...